Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Survival data on drug in phase 3 trial for metastatic breast cancer reported
June 16th, 2005
YM BioSciences Inc. (YMBA), a cancer product development company, announced that updated results for a completed phase 3 metastatic breast cancer trial using the company's drug tesmilifene, were released in conjunction with an abstract published in the Proceedings of the 2005 American Society of Clinical Oncology's (ASCO) annual meeting. The abstract (No. 756) describes an analysis of overall survival in a subgroup of patients enrolled in the "MA.19" trial. A total of 305 patients were enrolled in the MA.19 trial. Of the 191 patients in whom cancer metastasized or recurred within 36 months from original diagnosis to trial entry, patients in the arm...
Source: Women's Health Weekly (2005-06-16)
|
